Targets › ALOX5AP
1 program from 1 company in 1 trial: 1 Phase 2; Cardiovascular; next expected readout Dec 2026.
Required for leukotriene biosynthesis by ALOX5 (5-lipoxygenase). Anchors ALOX5 to the membrane. (UniProt, P20292)
Open in Phaseline: the race on ALOX5AP, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Kardigan | Tonlamarsen Antisense oligonucleotide targeting ALOX5AP; reduces leukotriene production to lower blood | ALOX5AP | Phase 2 | Hypertension | Dec 2026 |
Hypertension (1)
other (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.